Aller au contenu principal
Accès ouvert déclaré 2026 article

International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100

0Citations signalées — pas une note de qualité
58Institutions déclarées
21Pays d’affiliation déclarés

Résumé fourni par la source

INTRODUCTION: Cancer survivors face unique and persistent health-related quality of life (HRQoL) challenges. Existing HRQoL questionnaires for survivors lack content regarding chronic physical issues and have typically included limited cancer types and languages/cultures, affecting breadth of content and generalisability. We developed and validated the EORTC QLQ-SURV100, a questionnaire to assess HRQoL in disease-free survivors of diverse cancers. A conceptual framework of HRQoL in cancer survivors, developed in previous study phases and conceptualised as survivors' self-reported physical, mental and social functioning and well-being, formed the basis for questionnaire content. METHODS: The QLQ-SURV100 was administered to 1480 participants across 46 centres in 21 countries (31% breast cancer, 23% colorectal, 22% prostate, 24% other cancers), who had completed primary treatment 1-10 years earlier and had no evidence of active disease. Structural validity of the 21 multi-item questionnaire scales was assessed via confirmatory factor analysis; test-retest reliability via intraclass correlation coefficients (ICCs); construct validity through known-group comparisons; and cross-cultural validity and sex invariance through differential item functioning (DIF). Item response theory (IRT) analyses evaluated item redundancy and performance. RESULTS: The QLQ-SURV100 showed strong structural validity (Comparative Fit Index = 0.951; Tucker-Lewis Index = 0.944; Root Mean Square Error of Approximation = 0.046), with most standardised factor loadings > 0.7. Test-retest ICCs exceeded 0.7 for 27 of 35 scales and 0.6 for 34 scales. Known-groups analyses supported most hypotheses, confirming sensitivity to treatment, comorbidity, age, sex, and education. DIF analysis indicated minor cross-cultural item bias, but no sex-related DIF. IRT analysis found no redundant items. CONCLUSIONS: The EORTC QLQ-SURV100 showed satisfactory structural validity, test-retest reliability and construct validity; limited item redundancy; and measurement invariance across the sex and language groups examined.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100
Date Crossref
01/09/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

King's College LondonDutch Cancer SocietyUniversity Health NetworkUniversity of TorontoPrincess Margaret Cancer CentreKing Hussein Cancer CenterSunnybrook Health Science CentreNational Center for Tumor DiseasesNationales Centrum für Tumorerkrankungen DresdenSt James's University HospitalNational University Hospital of IcelandSamsung Medical CenterVrije Universiteit BrusselUniversitair Ziekenhuis BrusselUniversity of Modena and Reggio EmiliaAzienda Sanitaria Unità Locale di Reggio EmiliaDanish Cancer SocietyGerman Cancer Research CenterHeidelberg UniversityMuğla UniversityTokyo National HospitalGhent University HospitalGhent UniversityUniversität HamburgUniversity Medical Center Hamburg-EppendorfUniversity Cancer Center HamburgCentro di Riferimento OncologicoNavarre Institute of Health ResearchNavarrabiomedIstituti di Ricovero e Cura a Carattere ScientificoRoyal Devon & Exeter NHS Foundation TrustSalisbury NHS Foundation TrustUniversity of Southern DenmarkOdense University HospitalNational Center for Global Health and MedicineHarokopio University of AthensUniversity of SouthamptonUniversity of CopenhagenFrederiksberg HospitalPeter MacCallum Cancer CentreMount Vernon Cancer CentreSheba Medical CenterPoole HospitalUniversity of RijekaIstituto Scientifico Romagnolo per lo Studio e la Cura dei TumoriAmsterdam NeuroscienceAnadolu UniversityAzienda Ospedaliera Sant'AndreaUniversity Hospital HeidelbergOslo University HospitalBank of Cyprus Oncology CenterIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Nagano National HospitalSørlandet SykehusLeiden University Medical CenterAdministração Regional de Saúde de Lisboa e Vale do TejoAin Shams UniversityUniversity Hospital Complex Of Vigo

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Cancer survivorship and careFrailty in Older AdultsChildhood Cancer Survivors' Quality of Life

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.